Skip to search formSkip to main contentSkip to account menu

RG7204

Known as: RG 7204, RG-7204 
National Institutes of Health

Related topics

Related topics

2 relations
PLX4032

Broader (1)

Vemurafenib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Title Combination Treatment for Melanoma Permalink
Combining immunotherapy with targeted therapy blocking oncogenic BRAF may result in improved treatments for advanced melanoma. In… 
2012
2012
Abstract 2156: Preclinical combinations of vemurafenib, a selective BRAF inhibitor, with other targeted therapies in BRAFV600Ecolorectal cancer models
Mutations in BRAF at codon 600 promote catalytic activity and are associated with 8% of all human (solid) tumors, including about… 
2012
2012
Efficacy of vemurafenib, a selective BRAFV600E inhibitor, in combination with a MEK inhibitor in BRAFV600E colorectal cancer models.
488 Background: BRAF mutations occur in about 10% of colorectal cancer (CRC). Most BRAF mutations involve the V600E amino acid… 
2011
2011
Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy.
8520 Background: Vemurafenib (V; RG7204, PLX4032), an oral inhibitor of oncogenic V600E mutant BRAF, was evaluated for safety… 
2011
2011
Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas.
LBA4 The full, final text of this abstract will be available in Part II of the 2011 Annual Meeting Proceedings, distributed… 
Review
2011
Review
2011
[Advances in clinical treatment of malignant melanoma: B-RAF kinase inhibition].
Malignant melanoma is an aggressive cancer of pigment-producing cells, derivates of the neural crest. Surgical resection is the… 
2011
2011
Abstract 2562: Efficacy of RG7204 (PLX4032), a selective BRAFV600Einhibitor, in combination with pegylated interferon alpha-2a (Pegasys), paclitaxel, carboplatin, and anti-VEGF MAb B20-4.1 in the LOX…
Few drugs are currently approved for the treatment of melanoma, including dacarbazine (chemotherapy) and interferon alpha… 
2011
2011
Dual fronts poised to transform melanoma therapy
With recent successes of immunotherapies and targeted drugs, melanoma has become one of the most dynamic areas of anticancer drug… 
2010
2010
PLX4032 (RG7204), a selective mutant RAF inhibitor: Clinical and histologic characteristics of therapy-associated cutaneous neoplasms in a phase I trial.
8592 Background: Tumor regressions have been observed in a significant proportion of advanced melanoma patients treated with… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)